- Home
- SCPH vs GNFT Comparison
SCPH vs GNFT Comparison
Compare SCPH & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- GNFT
- Stock Information
- Founded
- SCPH 2013
- GNFT 1999
- Country
- SCPH United States
- GNFT France
- Employees
- SCPH N/A
- GNFT N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCPH Health Care
- GNFT Health Care
- Exchange
- SCPH Nasdaq
- GNFT Nasdaq
- Market Cap
- SCPH 179.6M
- GNFT 172.2M
- IPO Year
- SCPH 2017
- GNFT 2019
- Fundamental
- Price
- SCPH $3.24
- GNFT $3.66
- Analyst Decision
- SCPH Strong Buy
- GNFT Strong Buy
- Analyst Count
- SCPH 2
- GNFT 1
- Target Price
- SCPH $15.00
- GNFT $13.00
- AVG Volume (30 Days)
- SCPH 412.0K
- GNFT 6.9K
- Earning Date
- SCPH 03-12-2025
- GNFT 09-19-2024
- Dividend Yield
- SCPH N/A
- GNFT N/A
- EPS Growth
- SCPH N/A
- GNFT N/A
- EPS
- SCPH N/A
- GNFT 0.47
- Revenue
- SCPH $30,278,000.00
- GNFT $86,225,222.00
- Revenue This Year
- SCPH $172.64
- GNFT $145.20
- Revenue Next Year
- SCPH $131.43
- GNFT N/A
- P/E Ratio
- SCPH N/A
- GNFT $7.56
- Revenue Growth
- SCPH 303.87
- GNFT 175.45
- 52 Week Low
- SCPH $3.08
- GNFT $3.35
- 52 Week High
- SCPH $6.54
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- SCPH 40.08
- GNFT 44.80
- Support Level
- SCPH $3.27
- GNFT $3.35
- Resistance Level
- SCPH $3.59
- GNFT $3.57
- Average True Range (ATR)
- SCPH 0.20
- GNFT 0.11
- MACD
- SCPH -0.01
- GNFT 0.02
- Stochastic Oscillator
- SCPH 15.00
- GNFT 56.36
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.